Uttar Pradesh News Desk

IgA Nephropathy (IgAN) Market Size and Share Analysis, Growth Opportunities, Current Treatment Practices, Emerging Therapies, Epidemiology Forecast | Key Companies – Astellas Pharma

 Breaking News
  • No posts were found

IgA Nephropathy (IgAN) Market Size and Share Analysis, Growth Opportunities, Current Treatment Practices, Emerging Therapies, Epidemiology Forecast | Key Companies – Astellas Pharma

July 13
02:14 2022
IgA Nephropathy (IgAN) Market Size and Share Analysis, Growth Opportunities, Current Treatment Practices, Emerging Therapies, Epidemiology Forecast | Key Companies - Astellas Pharma
DelveInsight’s “IgA Nephropathy (IgAN) Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the IgA Nephropathy (IgAN), historical and forecasted epidemiology as well as the IgA Nephropathy (IgAN) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “IgA Nephropathy (IgAN) Market Insights, Epidemiology, and Market Forecast-2032”. 

 

DelveInsight’s “IgA Nephropathy (IgAN) Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the IgA Nephropathy (IgAN), historical and forecasted epidemiology as well as the IgA Nephropathy (IgAN) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

 

Some of the key facts of the IgA Nephropathy (IgAN) Market Report: 

  • The market size of IgA Nephropathy was estimated to be USD 200 million in the year 2021 
  • IgA Nephropathy is the most common glomerular disease worldwide but varies largely geographically
  • In 2021, the total prevalent cases of IgA nephropathy were the highest in China, with approximately 1.3 million cases, and the lowest in Spain with around 20,000 
  • In the United States, there were over 60,000 cases in the age group of 45–64 years, which is expected to rise in 2032 
  • Ad per the studies, IgA Nephropathy is more prominent in males in comparison to females 
  • Among EU5 countries, Germany had the highest number of prevalent cases of IgA nephropathy (~32,000 cases) in 2021 

 

Request a sample for the Report: https://www.delveinsight.com/sample-request/iga-nephropathy-market

 

Key benefits of the report:

  1. IgA Nephropathy (IgAN) market report covers a descriptive overview and comprehensive insight of the IgA Nephropathy (IgAN) Epidemiology and IgA Nephropathy (IgAN)  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The IgA Nephropathy (IgAN) market report provides insights on the current and emerging therapies.
  3. IgA Nephropathy (IgAN) market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The IgA Nephropathy (IgAN) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the IgA Nephropathy (IgAN) market.

 

Got queries? Click here to know more about the IgA Nephropathy (IgAN) Market Landscape 

 

IgA Nephropathy (IgAN) Overview: 

IgA Nephropathy (IgAN) is an autoimmune disease that attacks the kidneys. It affects blood filtration in the small blood vessels of the kidneys. IgAN occurs when an abnormal protein damages the filtering unit (glomerulus) inside the kidneys. 

IgAN is the most common glomerular disease worldwide but varies largely geographically. Studies assess the prevalence of IgAN in different regions and analyze factors responsible for geographic differences. According to one such prominent study, IgAN is more frequent in Asian populations (45 cases per million population in Japan) than in Caucasians (31 cases per million population/y in France). 

 

IgA Nephropathy (IgAN) Symptoms:

The symptoms of IgA Nephropathy include –

  • Cola or Tea colored urine discharge
  • Visible blood in urine
  • High blood pressure
  • Swelling in the ankle
  • Pain in the sides of the back 

 

IgA Nephropathy (IgAN) Market  

The dynamics of the IgA Nephropathy (IgAN) market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as LNP023, HR19042 Capsules, and others during the forecasted period 2019-2032. 

 

Learn more by requesting for sample @IgA Nephropathy (IgAN) Market Landscape  

 

IgA Nephropathy (IgAN) Pipeline Therapies:

  • Budesonide
  • Tacrolimus
  • LNP023
  • HR19042 Capsules 

 

IgA Nephropathy (IgAN) Pipeline Key Companies:

  • Astellas Pharma 
  • Chinook Therapeutics
  • Jiangsu HengRui Medicine Co.
  • Novartis Pharmaceuticals

 

Table of Contents 

1. IgA Nephropathy (IgAN) Market Report Introduction

2. Executive Summary

3. SWOT analysis

4. IgA Nephropathy (IgAN) Patient Share (%) Overview at a Glance

5. IgA Nephropathy (IgAN) Market Overview at a Glance

6. IgA Nephropathy (IgAN) Disease Background and Overview

7. IgA Nephropathy (IgAN) Epidemiology and Patient Population

8. Country-Specific Patient Population of IgA Nephropathy (IgAN) 

9. IgA Nephropathy (IgAN) Current Treatment and Medical Practices

10. IgA Nephropathy (IgAN) Unmet Needs

11. IgA Nephropathy (IgAN) Emerging Therapies

12. IgA Nephropathy (IgAN) Market Outlook

13. Country-Wise IgA Nephropathy (IgAN) Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. IgA Nephropathy (IgAN) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight 

 

Click here to read more about IgA Nephropathy (IgAN) Market Outlook 2032

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

Related Articles